Walker Robert Edward 4

4 · NOVAVAX INC · Filed Apr 16, 2026

AI-generated summary of this filing

Updated Apr 16, 2026

Novavax (NVAX) EVP R&D Walker Receives Option & RSU Awards

What Happened

Walker Robert Edward, Executive Vice President, R&D at Novavax (NVAX), received two equity awards on April 14, 2026: a stock option covering 99,500 shares and 66,000 restricted stock units (RSUs). Both awards are recorded at $0.00 (awarded, not purchased), so there was no cash paid by Walker.
The option and RSU grants are derivative awards (not open‑market buys or sells) and will vest over time according to the company plan terms.

Key Details

Transaction date: April 14, 2026; Form 4 filed April 16, 2026 (within the typical 2-business-day reporting window).
Reported price: $0.00 for both grants (A = award/grant).
Option grant: 99,500 shares. Vesting: 25% vests on first anniversary, remaining 75% vests in equal monthly installments over the following three years (see footnote F1).
RSU grant: 66,000 RSUs. Each RSU converts to one share if vested; RSUs vest one‑third on each of the first three anniversaries of the grant (see footnotes F2 and F3).
Shares owned after the transaction: not specified in the details you provided in this filing.
No immediate sale or cashless exercise reported—these are time‑based awards subject to continued employment.

Context

Options give the holder the right to buy company stock at a set price (vesting schedule must be met first); RSUs are promises to deliver shares once vesting conditions are satisfied. These awards are common as compensation and do not by themselves indicate buying or selling sentiment.

Form 4

Period: 2026-04-14

EVP, R&D

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-04-14+99,500→ 99,500 total
Exercise: $8.46Exp: 2036-04-14→ Common Stock (99,500 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-04-14+66,000→ 6,600 total
→ Common Stock (66,000 underlying)

Footnotes (3)

[F1]Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
[F2]Each RSU represents a contingent right to receive one share of the "Company" common stock.
[F3]The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.

Signature

/s/ Mark J. Casey, Attorney-in-Fact|2026-04-16

1 file